CPC A61K 39/39591 (2013.01) [A61K 38/1793 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/42 (2013.01); A61K 47/60 (2017.08); C07K 16/22 (2013.01); C07K 16/241 (2013.01); C07K 16/32 (2013.01); C12N 9/2462 (2013.01); C12N 9/96 (2013.01); C12Y 302/01017 (2013.01)] | 25 Claims |
1. An injectable liquid pharmaceutical formulation comprising:
a) at least about 10 mg/ml therapeutic antibody;
b) a viscosity reducing amount of caffeine, wherein the viscosity reducing amount of caffeine is 2% or less by weight of the injectable liquid pharmaceutical formulation; and
c) a viscosity reducing amount of an aromatic acid,
wherein viscosity of the injectable liquid pharmaceutical formulation is less than about 100 cP.
|